Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly

Jim C. Hu, Stephen Williams, Stacey C. Carter, Scott E. Eggener, Sandip Prasad, Karim Chamie, Quoc Dien Trinh, Maxine Sun, Paul L. Nguyen, Stuart R. Lipsitz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVES: To perform a population-based analysis to characterize the effect of prostate-specific antigen (PSA) testing on oncologic outcomes in men diagnosed with prostate cancer.

MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-Medicare-linked data to identify 98,883 men diagnosed with prostate cancer from 1996 to 2007. We stratified frequency of PSA testing as none, 1 to 2, 3 to 5, and≥6 tests in the 5 years before prostate cancer diagnosis. We used propensity scoring methods to assess the effect of frequency of PSA testing on likelihood of (1) metastases at diagnosis and (2) overall mortality and prostate cancer-specific mortality.

RESULTS: In adjusted analyses, the likelihood of being diagnosed with metastatic prostate cancer decreased with greater frequency of PSA testing (none, 10.6; 1-2, 8.3; 3-5, 3.7; and≥6, 2.5 events per 100 person years, P<0.001). Additionally, greater frequency of PSA testing was associated with improved overall survival and prostate cancer-specific survival (P<0.001 for both).

CONCLUSIONS: Greater frequency of PSA testing in men 70 years of age or older in the 5 years before prostate cancer diagnosis is associated with lower likelihood of being diagnosed with metastatic prostate cancer and improved overall and prostate cancer-specific survival.

Original languageEnglish (US)
JournalUrologic Oncology
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Population
Survival
Mortality
Medicare
Epidemiology
Research Design
Neoplasm Metastasis

Keywords

  • Elderly
  • Mortality
  • Prostate-specific antigen
  • PSA
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. / Hu, Jim C.; Williams, Stephen; Carter, Stacey C.; Eggener, Scott E.; Prasad, Sandip; Chamie, Karim; Trinh, Quoc Dien; Sun, Maxine; Nguyen, Paul L.; Lipsitz, Stuart R.

In: Urologic Oncology, Vol. 33, No. 2, 01.02.2015.

Research output: Contribution to journalArticle

Hu, JC, Williams, S, Carter, SC, Eggener, SE, Prasad, S, Chamie, K, Trinh, QD, Sun, M, Nguyen, PL & Lipsitz, SR 2015, 'Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly', Urologic Oncology, vol. 33, no. 2. https://doi.org/10.1016/j.urolonc.2014.06.003
Hu, Jim C. ; Williams, Stephen ; Carter, Stacey C. ; Eggener, Scott E. ; Prasad, Sandip ; Chamie, Karim ; Trinh, Quoc Dien ; Sun, Maxine ; Nguyen, Paul L. ; Lipsitz, Stuart R. / Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. In: Urologic Oncology. 2015 ; Vol. 33, No. 2.
@article{87a681959d3e446f9f9acfb06fe9314a,
title = "Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly",
abstract = "OBJECTIVES: To perform a population-based analysis to characterize the effect of prostate-specific antigen (PSA) testing on oncologic outcomes in men diagnosed with prostate cancer.MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-Medicare-linked data to identify 98,883 men diagnosed with prostate cancer from 1996 to 2007. We stratified frequency of PSA testing as none, 1 to 2, 3 to 5, and≥6 tests in the 5 years before prostate cancer diagnosis. We used propensity scoring methods to assess the effect of frequency of PSA testing on likelihood of (1) metastases at diagnosis and (2) overall mortality and prostate cancer-specific mortality.RESULTS: In adjusted analyses, the likelihood of being diagnosed with metastatic prostate cancer decreased with greater frequency of PSA testing (none, 10.6; 1-2, 8.3; 3-5, 3.7; and≥6, 2.5 events per 100 person years, P<0.001). Additionally, greater frequency of PSA testing was associated with improved overall survival and prostate cancer-specific survival (P<0.001 for both).CONCLUSIONS: Greater frequency of PSA testing in men 70 years of age or older in the 5 years before prostate cancer diagnosis is associated with lower likelihood of being diagnosed with metastatic prostate cancer and improved overall and prostate cancer-specific survival.",
keywords = "Elderly, Mortality, Prostate-specific antigen, PSA, Survival",
author = "Hu, {Jim C.} and Stephen Williams and Carter, {Stacey C.} and Eggener, {Scott E.} and Sandip Prasad and Karim Chamie and Trinh, {Quoc Dien} and Maxine Sun and Nguyen, {Paul L.} and Lipsitz, {Stuart R.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.urolonc.2014.06.003",
language = "English (US)",
volume = "33",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly

AU - Hu, Jim C.

AU - Williams, Stephen

AU - Carter, Stacey C.

AU - Eggener, Scott E.

AU - Prasad, Sandip

AU - Chamie, Karim

AU - Trinh, Quoc Dien

AU - Sun, Maxine

AU - Nguyen, Paul L.

AU - Lipsitz, Stuart R.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - OBJECTIVES: To perform a population-based analysis to characterize the effect of prostate-specific antigen (PSA) testing on oncologic outcomes in men diagnosed with prostate cancer.MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-Medicare-linked data to identify 98,883 men diagnosed with prostate cancer from 1996 to 2007. We stratified frequency of PSA testing as none, 1 to 2, 3 to 5, and≥6 tests in the 5 years before prostate cancer diagnosis. We used propensity scoring methods to assess the effect of frequency of PSA testing on likelihood of (1) metastases at diagnosis and (2) overall mortality and prostate cancer-specific mortality.RESULTS: In adjusted analyses, the likelihood of being diagnosed with metastatic prostate cancer decreased with greater frequency of PSA testing (none, 10.6; 1-2, 8.3; 3-5, 3.7; and≥6, 2.5 events per 100 person years, P<0.001). Additionally, greater frequency of PSA testing was associated with improved overall survival and prostate cancer-specific survival (P<0.001 for both).CONCLUSIONS: Greater frequency of PSA testing in men 70 years of age or older in the 5 years before prostate cancer diagnosis is associated with lower likelihood of being diagnosed with metastatic prostate cancer and improved overall and prostate cancer-specific survival.

AB - OBJECTIVES: To perform a population-based analysis to characterize the effect of prostate-specific antigen (PSA) testing on oncologic outcomes in men diagnosed with prostate cancer.MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-Medicare-linked data to identify 98,883 men diagnosed with prostate cancer from 1996 to 2007. We stratified frequency of PSA testing as none, 1 to 2, 3 to 5, and≥6 tests in the 5 years before prostate cancer diagnosis. We used propensity scoring methods to assess the effect of frequency of PSA testing on likelihood of (1) metastases at diagnosis and (2) overall mortality and prostate cancer-specific mortality.RESULTS: In adjusted analyses, the likelihood of being diagnosed with metastatic prostate cancer decreased with greater frequency of PSA testing (none, 10.6; 1-2, 8.3; 3-5, 3.7; and≥6, 2.5 events per 100 person years, P<0.001). Additionally, greater frequency of PSA testing was associated with improved overall survival and prostate cancer-specific survival (P<0.001 for both).CONCLUSIONS: Greater frequency of PSA testing in men 70 years of age or older in the 5 years before prostate cancer diagnosis is associated with lower likelihood of being diagnosed with metastatic prostate cancer and improved overall and prostate cancer-specific survival.

KW - Elderly

KW - Mortality

KW - Prostate-specific antigen

KW - PSA

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85006271493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006271493&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.06.003

DO - 10.1016/j.urolonc.2014.06.003

M3 - Article

VL - 33

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -